Author (Corporate) | European Medicines Agency |
---|---|
Series Title | Press Release |
Series Details | EMA/CHMP/428277/2010 (6.7.10) |
Publication Date | 06/07/2010 |
Content Type | News |
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has revised its previous recommendations on the use of Fabrazyme (agalsidase beta). This follows information from the manufacturer, Genzyme, stating that the current supply of Fabrazyme will not address the medical needs of the nearly 600 patients receiving Fabrazyme in Europe today. Fabrazyme is used to treat the rare, inherited enzyme-deficiency disorder, Fabry disease. |
|
Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/07/news_detail_001046.jsp&mid=WC0b01ac058004d5c1 |
Related Links |
|
Subject Categories | Health |
Countries / Regions | Europe |